

REMARKS/ARGUMENTS

The present amendment after final rejection cancels Claims 1-3, 5 and 10. Claims 4 and 7-9 stand canceled. New Claim 11 is sought to be added.

Upon entry of the amendment the claims will be 6 and 11.

Claim 6 is amended as suggested in the Advisory Action for favorable consideration by the Examiner.

Basis for the recitation "treating hypertriglyceridemia" appears in the specification at page 6, the paragraph at line 2. That a synergistically effective combination exists for the stated purpose is demonstrated in the Example, pages 8-10, reinforced by the declaration of Taro Aoki.

New Claim 11 depends from Claim 6 and presents the preferred species of the components of the combination recited in Claim 6. No new issue arises since the combination was recited in deleted Claim 10.

The amendments to the specification presented in the previously filed Amendment After Final Rejection are resubmitted. The Advisory Action presents no criticism of these amendments.

The cancellation of claims 1-3, 5 and 10 renders the rejections of them moot.

Entry of the amendments and favorable reconsideration is solicited. No new issues are raised and the number of claims is reduced.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Milton Sterman
Registration No. 27,499

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)